Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumors
Yen-Lin Huang(National Taiwan University), Shang‐Gin Wu(National Taiwan University), Derek De-Rui Huang(National Taiwan University Hospital), James Chih‐Hsin Yang(National Taiwan University Hospital), Chia‐Chi Hsu(National Taiwan University Hospital)
Cited by 9
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k